Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
The purpose of this study is to help children who are tube-fed transition to eating orally. The goal is to evaluate the effectiveness of treatment with an experimental drug (megestrol) as part of a 24-week behavioral feeding protocol in transitioning from tube to oral feedings in a pediatric population. All children will receive feeding skills coaching to help them learn to eat by mouth, and children will follow a tube weaning protocol to transition from tube to oral feeds. More information can be found at www.ikaneat.org
The purpose of this study is to test an investigational medication in children and adolescents aged 5-17 years old with irritability associated with autism spectrum disorder (ASD). The name of the medication being tested in this study is pimavanserin. This medication is investigational because it has not been approved by the FDA for the treatment of irritability associated with autism. The main risks of this study are from the medication, which include nausea, dizziness, and sleepiness.
If you are eligible and agree to participate, you will be randomly assigned to receive either placebo (a pill with no medication in it) or the study medication. Participation will last approximately 15 weeks and involve 8 study visits and one phone call. You will need to take the study drug for 6 weeks.
Getting a driver’s license is something that teens-including those with Congenital Heart Disease (CHD)-may look forward to. Although we know a lot about teenage driving and the programs in place to support learning this skill, we know very little about the early driving experiences of teenagers with CHD.
We are looking for teens with CHD who are 15 to 19 years old and have a learner’s permit or valid driver’s license, or interest in obtaining a learner’s permit or driver’s license and their parent/legal guardian. The study will be conducted remotely.
The electronic health record will be reviewed by a member of the study team, and teens and parents/legal guardians will be asked to complete demographic and health assessment surveys. Each teen and parent will participate in separate 45-minute video interviews to talk about what things support driving with a CHD and things that might make it harder to do. The video interview will take place on a video conferencing site using a computer or smartphone.
The total study participation time for each person (teen and parent/legal guardian) is 60 minutes. All teens and parents/legal guardians who participate will be compensated for their effort.
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of the study drug are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing sarcoma.
This is a study to measure the effectiveness of the medication voclosporin compared to placebo in adolescent patients with active lupus nephritis. Volcosporin is an outpatient, oral medication.
This two-phase study is being conducted to determine the reasons why some children with newly diagnosed Crohn's disease heal their bowel inflammation after one type of therapy and why others do not. To do this, the study team will ask to collect blood, stool and biopsy (tissue) samples from participants newly diagnosed with Crohn's disease to measure their inflammation markers and evaluate their genes (DNA). To determine how much a participant's bowels have healed, we will also compare colonoscopy and MRE results that occur as part of the participant's standard clinical care.
This research is studying a vaccine against Mpox (formerly known as monkeypox) that is FDA approved for adults but not yet approved for children. The goal of the study is to determine if the vaccine protects children just as well as it protects adults. The study is also looking at the safety of the vaccine. This study is open to healthy adolescents, ages 12-17. In addition, adolescents with certain immunodeficiency diseases or other conditions, that are well controlled, are eligible to participate.
This study is being done to understand how the brain of autistic adolescents and adults process sound and language. We hope the information gained from this study may lead to future therapies for language difficulties in autistic individuals.
This study aims to design and optimize the Hypothyroidism Treatment Satisfaction Questionnaire (ThyTSQ) for measuring treatment satisfaction among teenage patients on thyroid hormone supplementation and parents of children of any age treated for hypothyroidism.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.